Harpoon Therapeutics to Participate in Two Upcoming Virtual Conferences
Harpoon Therapeutics, Inc. (NASDAQ: HARP) announced that Dr. Gerald McMahon, President and CEO, will participate in two virtual investor conferences. The first is a fireside chat at Baird’s 2020 Global Healthcare Conference on September 9, 2020, at 3:45 p.m. ET, followed by a panel at Citi's BioPharma Virtual Conference on September 10, 2020, at 10:45 a.m. ET. Investors can access a live audio webcast of the Baird chat on Harpoon's website, with an archived replay available later. Harpoon focuses on T cell engagers for cancer treatment using its proprietary TriTAC platform.
- None.
- None.
SOUTH SAN FRANCISCO, Calif., Sept. 02, 2020 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that Gerald McMahon, Ph.D., President and Chief Executive Officer, will participate in two upcoming virtual investor conferences:
- A fireside chat at Baird’s 2020 Global Healthcare Conference on Wednesday, September 9, 2020 at 3:45 p.m. ET / 12:45 p.m. PT; and
- A “Novel Antibodies and Protein Therapeutics in Oncology” panel at Citi's 15th Annual BioPharma Virtual Conference on Thursday, September 10, 2020 at 10:45 a.m. ET / 7:45 a.m. PT.
A live audio webcast of the fireside chat at the Baird conference will be available in the Investors section of Harpoon Therapeutics’ website at www.harpoontx.com with an archived replay available following the event.
About Harpoon Therapeutics
Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct (TriTAC®) platform, Harpoon is developing a pipeline of novel TriTACs initially focused on the treatment of solid tumors and hematologic malignancies. HPN424 targets PSMA and is in a Phase 1/2a trial for metastatic castration-resistant prostate cancer. HPN536 targets mesothelin and is in a Phase 1/2a trial for cancers expressing mesothelin, initially focused on ovarian and pancreatic cancers. HPN217 targets BCMA and is in a Phase 1/2 trial for relapsed, refractory multiple myeloma. HPN328 targets DLL3 and Harpoon plans to initiate a Phase 1/2 trial in the second half of 2020. For additional information about Harpoon Therapeutics, please visit www.harpoontx.com.
Cautionary Note on Forward-looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “target,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Harpoon Therapeutics’ expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties that could cause Harpoon Therapeutics’ clinical development programs, future results or performance to differ significantly from those expressed or implied by the forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements about the progress, timing, scope and anticipated results of clinical trials, the timing of the presentation of data, the association of data with potential treatment outcomes, the development and advancement of product candidates, the timing of development milestones for product candidates, and the anticipated potential impacts to Harpoon Therapeutics’ business from the ongoing COVID-19 pandemic. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during clinical studies, clinical trial site activation or enrollment rates that are lower than expected, unanticipated or greater than anticipated impacts or delays due to COVID-19, changes in expected or existing competition, changes in the regulatory environment, the uncertainties and timing of the regulatory approval process, and unexpected litigation or other disputes. Other factors that may cause Harpoon Therapeutics’ actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Harpoon Therapeutics’ filings with the U.S. Securities and Exchange Commission, including the “Risk Factors” sections contained therein. Except as required by law, Harpoon Therapeutics assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.
Contacts:
Harpoon Therapeutics, Inc.
Georgia Erbez
Chief Financial Officer
650-443-7400
media@harpoontx.com
Westwicke ICR
Robert H. Uhl
Managing Director
858-356-5932
robert.uhl@westwicke.com
FAQ
What events will Harpoon Therapeutics participate in September 2020?
What is the focus of Harpoon Therapeutics' current development?
Where can I find the audio webcast for Harpoon's fireside chat?
What trials are currently underway for Harpoon Therapeutics' products?
What is the stock symbol for Harpoon Therapeutics?
